Towards "CO in a pill": Pharmacokinetic studies of carbon monoxide prodrugs in mice.

ABSTRACT: Carbon monoxide (CO) is a known endogenous signaling molecule with potential therapeutic indications in treating inflammation, cancer, neuroprotection, and sickle cell disease among many others. One of the hurdles in using CO as a therapeutic agent is the development of pharmaceutically acceptable delivery forms for various indications. Along this line, we have developed organic CO prodrugs that allow for packing this gaseous molecule into a dosage form for the goal of "carbon monoxide in a pill." This should enable non-inhalation administration including oral and intravenous routes. These prodrugs have previously demonstrated efficacy in multiple animal models. To further understand the CO delivery efficiency of these prodrugs in relation to their efficacy, we undertook the first pharmaco

SUBMITTER: Wang M 

PROVIDER: S-EPMC7606817 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature